| Identification | Back Directory | [Name]
Pyrrolo[1,2-a]pyrazine-1,4-dione, hexahydro-8a-2-propen-1-yl-, (8aR)- | [CAS]
847952-38-9 | [Synonyms]
Pyrrolo[1,2-a]pyrazine-1,4-dione, hexahydro-8a-2-propen-1-yl-, (8aR)- | [Molecular Formula]
C10H14N2O2 | [MOL File]
847952-38-9.mol | [Molecular Weight]
194.23 |
| Hazard Information | Back Directory | [Uses]
NNZ 2591 is a synthetic analogue of a small peptide of cyclic glycine proline (cGP). NNZ 2591 shows orally active and cross the blood-brain barrier. NNZ 2591 shows neuroprotective after ischemic brain injury. NNZ 2591 improves motor function in a rat model of Parkinson's disease. NNZ 2591 has the potential for the research of ischemic brain injury and angelman syndrome[1][2][3]. | [in vivo]
NNZ 2591 (30 mg/kg; p.o.) prevented scopolamine-induced memory impairment in rats[1].
NNZ 2591 (2, 20, 100 ng/rat; i.c.v.) shows neuroprotection in rats[2].
NNZ 2591 (3 mg/kg; s.c.; daily for 5 days) completely preventes brain damage and significantly reduces the L/R ratio of time taken to touch to the patch at 5 d after injury in rats[2]. | Animal Model: | 4 months, male young adult Wistar rats[1]. | | Dosage: | 30 mg/kg | | Administration: | P.o.; 10 min after the (scopolamine) i.p. administration. | | Result: | Significantly reduced the number of M2AchR positive neurons, significantly reduced the density of synaptophysin in the CA3 and CA4 sub-regions, and altered TH terminal staining in the striatum. |
| Animal Model: | 280-310 g adult male Wistar rats[2]. | | Dosage: | 2, 20, 100 ng/rat | | Administration: | I.c.v.; 2 h after HI injury | | Result: | Reduced overall tissue damage in the sub-regions of the hippocampus, DG, cerebral cortex and the striatum. |
| Animal Model: | 280-310 g adult male Wistar rats[2]. | | Dosage: | 3 mg/kg | | Administration: | S.c.; daily for 5 days | | Result: | Significantly reduced the median of tissue damage scores in the CA1-2, CA3 and CA4 sub-regions of the hippocampus, the DG. |
| [References]
[1] Guan J, et al. NNZ-2591, a novel diketopiperazine, prevented scopolamine-induced acute memory impairment in the adult rat. Behav Brain Res. 2010 Jul 11;210(2):221-8. DOI:10.1016/j.bbr.2010.02.039
[2] Guan J, et al. Peripheral administration of a novel diketopiperazine, NNZ 2591, prevents brain injury and improves somatosensory-motor function following hypoxia-ischemia in adult rats. Neuropharmacology. 2007 Nov;53(6):749-62. DOI:10.1016/j.neuropharm.2007.08.010
[3] Copping NA, et al. Emerging Gene and Small Molecule Therapies for the Neurodevelopmental Disorder Angelman Syndrome. Neurotherapeutics. 2021 Jul;18(3):1535-1547. DOI:10.1007/s13311-021-01082-x |
|
|